Osteosarcoma is a highly aggressive bone cancer primarily affecting children, adolescents, and young adults. The current gold standard for treatment of osteosarcoma patients consists of two to three ...

1 Department of Orthopedic Trauma, Zhuji People’s Hospital of Zhejiang Province, Zhuji, Zhejiang, China 2 Department of Emergency and Critical Care, Shanghai Changzheng Hospital, Shanghai, China ...

Objectives Investigating the effect of prognostic factors in a multistate framework on survival in a large population of patients with osteosarcoma. Of interest is how prognostic factors affect ...

OS Ther­a­pies is mov­ing ahead with plans for an ac­cel­er­at­ed ap­proval path­way af­ter its off-the-shelf can­di­date for peo­ple who have had surgery to treat os­teosar­co­ma … ...

These statistics include both adults and children. Certain types occur more often in certain parts of the body more often than others. For example, leiomyosarcomas are the most common type of sarcoma ...

The US FDA granted OST-HER2 rare pediatric disease designation for osteosarcoma in 2021. The US FDA rare pediatric disease PRV program aims to incentivize drug development for rare pediatric diseases.

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I drugs for Kaposi Sarcoma have an 84% phase transition success rate ...